What is the 13F Pro Quality Score for VVOS?

13F Pro ranks Vivos Therapeutics, Inc. (VVOS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VVOS's current score at https://13fpro.ai/research/VVOS (free sign-up required for the full ranking).

Where does 13F Pro source VVOS data?

All Vivos Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Vivos Therapeutics, Inc. files with the SEC under CIK 1716166. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VVOS in?

Vivos Therapeutics, Inc. (VVOS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VVOS research updated on 13F Pro?

VVOS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Vivos Therapeutics, Inc.(VVOS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1716166 VVOS stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $17.4M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

VVOS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Vivos Therapeutics, Inc. (VVOS), a Healthcare sector company. VVOS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $17.4m in revenue. Based on the latest XBRL financial filings (Q1 2026), Vivos Therapeutics, Inc. reports quarterly revenue of $5.1M, net income of $-7.7M, free cash flow of $-6.0M. Top institutional holders of VVOS by reported 13-F value include ARMISTICE CAPITAL,, GEODE CAPITAL MANAGEMENT,, COMMONWEALTH EQUITY SERVICES,, based on the most recent SEC filings. VVOS trades on the Nasdaq exchange and files with the SEC under CIK 1716166. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VVOS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vivos Therapeutics, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$5.1M

Net Income

Q1 2026

$-7.7M

Free Cash Flow

Q1 2026

$-6.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+26.4% YoY

$17.4MFY 2025

FY19 $11.4MFY22 $16.0MFY23 $13.8MFY25 $17.4M

Net Income

-55.9% YoY

$-21.2MFY 2025

FY19 $-10.8MFY22 $-23.8MFY23 $-13.6MFY25 $-21.2M

Operating Income

-15.0% YoY

$-19.9MFY 2025

FY19 $-10.6MFY22 $-25.0MFY23 $-17.3MFY25 $-19.9M

EPS (Diluted)

+81.4% YoY

$-2.07FY 2025

FY19 —FY22 $-25.90FY23 $-11.14FY25 $-2.07

Total Assets

+134.4% YoY

$25.2MFY 2025

FY19 $7.6MFY22 $13.7MFY23 $10.7MFY25 $25.2M

Total Debt

+837.8% YoY

$11.3MFY 2025

FY19 $7.4MFY22 —FY23 $1.2MFY25 $11.3M

Op. Cash Flow

-27.8% YoY

$-15.3MFY 2025

FY19 $-5.3MFY22 $-19.6MFY23 $-11.9MFY25 $-15.3M

Metric	FY 2025	FY 2023	FY 2022	FY 2019	FY 2018
Revenue	$17.4M +26.4%	$13.8M -13.9%	$16.0M +40.6%	$11.4M	—
Net Income	$-21.2M -55.9%	$-13.6M +43.0%	$-23.8M -121.7%	$-10.8M	—
Operating Income	$-19.9M -15.0%	$-17.3M +30.9%	$-25.0M -136.6%	$-10.6M	—
EPS (Diluted)	$-2.07 +81.4%	$-11.14 +57.0%	$-25.90	—	—
Total Assets	$25.2M +134.4%	$10.7M -21.8%	$13.7M +81.7%	$7.6M	—
Total Debt	$11.3M +837.8%	$1.2M	—	$7.4M	—
Operating Cash Flow	$-15.3M -27.8%	$-11.9M +39.0%	$-19.6M -266.8%	$-5.3M	—

AI Insight: VVOS Financial Trends

Vivos is burning cash while revenue stagnates, with debt doubling since Q2 2024 and equity now negative.

• Revenue volatile between $3–7M over 8 quarters with no sustained growth; latest Q1 2026 at $5M.

• Net loss widened from $2M in Q2 2024 to $8M in Q1 2026, nearly 4× worse despite flat revenue.

• Total debt rose from $1M (Q2 2024) to $8M (Q1 2026); equity collapsed to negative $1M.

• Operating cash flow consistently negative, ranging $3–6M burn per quarter with no improvement trend.

⚠ Negative shareholder equity signals balance sheet stress; solvency dependent on capital raise or operational turnaround.

⚠ Operating margin collapsed to −140% in Q1 2026 (Op Income $−7M on $5M revenue); unsustainable burn rate.

AI Insight: VVOS Ratio Trends

Vivos remains deeply unprofitable with deteriorating margins and surging leverage, showing no path to profitability in the data.

• Operating margin collapsed to -128.7% in Q1 2026 from -47.7% in Q2 2024, indicating severe cash burn acceleration.

• Net profit margin worsened to -149.4% in Q1 2026 versus -47.6% in Q2 2024, signaling widening net losses.

• Debt-to-equity spiked to 3.44x in Q3 2025 from 0.19x in Q2 2024, reflecting aggressive balance sheet deterioration.

⚠ D/E jumped from 1.73x to 3.44x between Q2–Q3 2025, then stabilized; monitor covenant compliance and refinancing risk.

⚠ Q4 2025 OpMargin hit -166.9%, worst quarter in dataset; Q1 2026 remains severely negative at -128.7%.

Get alerted when VVOS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Vivos Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VVOS

ARMISTICE CAPITAL, LLC
$1.3M1,115,859 sh
GEODE CAPITAL MANAGEMENT, LLC
$112.7K95,543 sh
COMMONWEALTH EQUITY SERVICES, LLC
$50.1K42,500 sh
IHT Wealth Management, LLC
$48.5K41,061 sh
Centurion Wealth Management LLC
$42.1K35,684 sh
B. Riley Wealth Advisors, Inc.
$41.5K38,066 sh
BlackRock, Inc.
$32.8K27,817 sh
XTX Topco Ltd
$29.6K25,117 sh
STATE STREET CORP
$29.4K24,922 sh
Sequoia Financial Advisors, LLC
$28.3K24,000 sh

Fund	Value	Shares
ARMISTICE CAPITAL, LLC	$1.3M	1,115,859
GEODE CAPITAL MANAGEMENT, LLC	$112.7K	95,543
COMMONWEALTH EQUITY SERVICES, LLC	$50.1K	42,500
IHT Wealth Management, LLC	$48.5K	41,061
Centurion Wealth Management LLC	$42.1K	35,684
B. Riley Wealth Advisors, Inc.	$41.5K	38,066
BlackRock, Inc.	$32.8K	27,817
XTX Topco Ltd	$29.6K	25,117
STATE STREET CORP	$29.4K	24,922
Sequoia Financial Advisors, LLC	$28.3K	24,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VVOS on your watchlist

Track score changes the day Vivos Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VVOS a good stock to buy?

13F Pro's AI-powered analysis of Vivos Therapeutics, Inc. (VVOS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VVOS are available on the VVOS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VVOS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VVOS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Vivos Therapeutics, Inc.'s investment landscape.